# Brown & Brown, Inc.: financial statements, quarterly

BRO · NYSE · CIK 79282 · [Financials](/sectors/financials.md) · fiscal year ends Jan 19

Pages: [Overview](/companies/bro.md) · [Financials](/companies/bro/financials.md) · [Filings](/companies/bro/filings.md) · [Insiders](/companies/bro/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bro/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,068](/filings/0000950170-24-117782.md) | [1,026 d](/filings/0001193125-26-046984.md) | [1,258](/filings/0000950170-25-059393.md) | [1,178](/filings/0000950170-25-099240.md) | [1,186](/filings/0001193125-25-251811.md) | [1,183 d](/filings/0001193125-26-046984.md) | [1,404](/filings/0001193125-26-182389.md) | [1,285](/filings/0001193125-26-318251.md) | [1,606](/filings/0001193125-25-251811.md) | [1,607 d](/filings/0001193125-26-046984.md) | [1,901](/filings/0001193125-26-182389.md) | [1,676](/filings/0001193125-26-318251.md) |
| Interest expense | $m | [47.5](/filings/0000950170-23-055281.md) | [47.9 d](/filings/0000950170-24-018890.md) | [48.0](/filings/0000950170-24-047140.md) | [49.0](/filings/0000950170-24-085353.md) | [50.0](/filings/0001193125-25-251811.md) | [46.0 d](/filings/0001193125-26-046984.md) | [46.0](/filings/0001193125-26-182389.md) | [51.0](/filings/0001193125-26-318251.md) | [100](/filings/0001193125-25-251811.md) | [100 d](/filings/0001193125-26-046984.md) | [99.0](/filings/0001193125-26-182389.md) | [100](/filings/0001193125-26-318251.md) |
| Income tax | $m | [66.0](/filings/0000950170-24-117782.md) | [86.0 d](/filings/0001193125-26-046984.md) | [71.0](/filings/0000950170-25-059393.md) | [87.0](/filings/0000950170-25-099240.md) | [78.0](/filings/0001193125-25-251811.md) | [64.0 d](/filings/0001193125-26-046984.md) | [93.0](/filings/0001193125-26-182389.md) | [77.0](/filings/0001193125-26-318251.md) | [82.0](/filings/0001193125-25-251811.md) | [53.0 d](/filings/0001193125-26-046984.md) | [106](/filings/0001193125-26-182389.md) | [94.0](/filings/0001193125-26-318251.md) |
| Net income | $m | [176](/filings/0000950170-24-117782.md) | [269 d](/filings/0001193125-26-046984.md) | [293](/filings/0000950170-25-059393.md) | [257](/filings/0000950170-25-099240.md) | [234](/filings/0001193125-25-251811.md) | [210 d](/filings/0001193125-26-046984.md) | [331](/filings/0001193125-26-182389.md) | [231](/filings/0001193125-26-318251.md) | [227](/filings/0001193125-25-251811.md) | [264 d](/filings/0001193125-26-046984.md) | [426](/filings/0001193125-26-182389.md) | [288](/filings/0001193125-26-318251.md) |
| Diluted EPS | $ per share | [0.62](/filings/0000950170-24-117782.md) | not reported | [1.02](/filings/0000950170-25-059393.md) | [0.90](/filings/0000950170-25-099240.md) | [0.81](/filings/0001193125-25-251811.md) | not reported | [1.15](/filings/0001193125-26-182389.md) | [0.78](/filings/0001193125-26-318251.md) | [0.68](/filings/0001193125-25-251811.md) | not reported | [1.06](/filings/0001193125-26-182389.md) | [0.84](/filings/0001193125-26-318251.md) |
| Basic EPS | $ per share | [0.62](/filings/0000950170-24-117782.md) | not reported | [1.03](/filings/0000950170-25-059393.md) | [0.90](/filings/0000950170-25-099240.md) | [0.82](/filings/0001193125-25-251811.md) | not reported | [1.16](/filings/0001193125-26-182389.md) | [0.79](/filings/0001193125-26-318251.md) | [0.68](/filings/0001193125-25-251811.md) | not reported | [1.27](/filings/0001193125-26-182389.md) | [0.86](/filings/0001193125-26-318251.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.8](/filings/0000950170-24-117782.md) | [0.7](/filings/0001193125-26-046984.md) | [0.6](/filings/0000950170-25-059393.md) | [1.1](/filings/0000950170-25-099240.md) | [1.0](/filings/0001193125-25-251811.md) | [0.7](/filings/0001193125-26-046984.md) | [0.7](/filings/0001193125-26-182389.md) | [8.9](/filings/0001193125-26-318251.md) | [1.2](/filings/0001193125-25-251811.md) | [1.1](/filings/0001193125-26-318251.md) | [1.0](/filings/0001193125-26-182389.md) | [0.9](/filings/0001193125-26-318251.md) |
| Current assets | $bn | [4.8](/filings/0000950170-23-055281.md) | [5.1](/filings/0000950170-25-019039.md) | [5.0](/filings/0000950170-24-047140.md) | [6.1](/filings/0000950170-24-085353.md) | [7.5](/filings/0000950170-24-117782.md) | [6.9](/filings/0001193125-26-046984.md) | [5.9](/filings/0000950170-25-059393.md) | [14.4](/filings/0000950170-25-099240.md) | [8.1](/filings/0001193125-25-251811.md) | [8.6](/filings/0001193125-26-318251.md) | [8.5](/filings/0001193125-26-182389.md) | [8.7](/filings/0001193125-26-318251.md) |
| Total assets | $bn | [14.0](/filings/0000950170-24-117782.md) | [14.9](/filings/0000950170-25-019039.md) | [14.8](/filings/0000950170-24-047140.md) | [15.9](/filings/0000950170-24-085353.md) | [17.5](/filings/0000950170-24-117782.md) | [17.6](/filings/0001193125-26-046984.md) | [16.8](/filings/0000950170-25-059393.md) | [25.6](/filings/0000950170-25-099240.md) | [29.4](/filings/0001193125-25-251811.md) | [30.0](/filings/0001193125-26-318251.md) | [29.7](/filings/0001193125-26-182389.md) | [29.9](/filings/0001193125-26-318251.md) |
| Current liabilities | $bn | [4.6](/filings/0000950170-23-055281.md) | [5.0](/filings/0000950170-25-019039.md) | [4.9](/filings/0000950170-24-047140.md) | [5.4](/filings/0000950170-24-085353.md) | [6.5](/filings/0000950170-24-117782.md) | [6.3](/filings/0001193125-26-046984.md) | [4.9](/filings/0000950170-25-059393.md) | [5.3](/filings/0000950170-25-099240.md) | [6.9](/filings/0001193125-25-251811.md) | [8.3](/filings/0001193125-26-318251.md) | [8.3](/filings/0001193125-26-182389.md) | [7.7](/filings/0001193125-26-318251.md) |
| Total liabilities | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $bn | [3.1](/filings/0000950170-23-055281.md) | [3.2](/filings/0000950170-25-019039.md) | [3.0](/filings/0000950170-24-047140.md) | [3.4](/filings/0000950170-24-085353.md) | [3.4](/filings/0000950170-24-117782.md) | [3.6](/filings/0001193125-26-046984.md) | [3.7](/filings/0000950170-25-059393.md) | [7.5](/filings/0000950170-25-099240.md) | [7.7](/filings/0001193125-25-251811.md) | [6.9](/filings/0001193125-26-318251.md) | [6.6](/filings/0001193125-26-182389.md) | [7.3](/filings/0001193125-26-318251.md) |
| Current portion of debt | $bn | [0.6](/filings/0000950170-23-055281.md) | [0.6](/filings/0000950170-25-019039.md) | [0.9](/filings/0000950170-24-047140.md) | [0.7](/filings/0000950170-24-085353.md) | [0.2](/filings/0000950170-24-117782.md) | [0.2](/filings/0001193125-26-046984.md) | [0.1](/filings/0000950170-25-059393.md) | [0.1](/filings/0000950170-25-099240.md) | [0.1](/filings/0001193125-25-251811.md) | [0.7](/filings/0001193125-26-318251.md) | [1.2](/filings/0001193125-26-182389.md) | [0.4](/filings/0001193125-26-318251.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [5.2](/filings/0000950170-23-055281.md) | [5.6](/filings/0000950170-24-018890.md) | [5.8](/filings/0001193125-25-251811.md) | [6.0](/filings/0001193125-25-251811.md) | [6.5](/filings/0001193125-25-251811.md) | [6.4](/filings/0001193125-26-318251.md) | [6.8](/filings/0001193125-26-318251.md) | [11.6](/filings/0001193125-26-318251.md) | [12.4](/filings/0001193125-25-251811.md) | [12.6](/filings/0001193125-26-318251.md) | [12.6](/filings/0001193125-26-318251.md) | [12.6](/filings/0001193125-26-318251.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [316 d](/filings/0000950170-24-117782.md) | [306 d](/filings/0001193125-26-046984.md) | [13.0](/filings/0000950170-25-059393.md) | [360 d](/filings/0000950170-25-099240.md) | [440 d](/filings/0001193125-25-251811.md) | [361 d](/filings/0001193125-26-046984.md) | [213](/filings/0001193125-26-182389.md) | [325 d](/filings/0001193125-26-318251.md) | [468 d](/filings/0001193125-25-251811.md) | [444 d](/filings/0001193125-26-046984.md) | [262](/filings/0001193125-26-182389.md) | [346 d](/filings/0001193125-26-318251.md) |
| Capital expenditure | $m | [13.8](/filings/0000950170-23-055281.md) | [31.0 d](/filings/0001193125-26-046984.md) | [13.0](/filings/0000950170-25-059393.md) | [26.0 d](/filings/0000950170-25-099240.md) | [23.0 d](/filings/0001193125-25-251811.md) | [20.0 d](/filings/0001193125-26-046984.md) | [17.0](/filings/0001193125-26-182389.md) | [15.0 d](/filings/0001193125-26-318251.md) | [16.0 d](/filings/0001193125-25-251811.md) | [20.0 d](/filings/0001193125-26-046984.md) | [21.0](/filings/0001193125-26-182389.md) | [17.0 d](/filings/0001193125-26-318251.md) |
| Dividends paid | $m | [33.0 d](/filings/0000950170-24-117782.md) | [37.0 d](/filings/0001193125-26-046984.md) | [38.0](/filings/0000950170-25-059393.md) | [37.0 d](/filings/0000950170-25-099240.md) | [36.0 d](/filings/0001193125-25-251811.md) | [43.0 d](/filings/0001193125-26-046984.md) | [43.0](/filings/0001193125-26-182389.md) | [43.0 d](/filings/0001193125-26-318251.md) | [51.0 d](/filings/0001193125-25-251811.md) | [56.0 d](/filings/0001193125-26-046984.md) | [57.0](/filings/0001193125-26-182389.md) | [55.0 d](/filings/0001193125-26-318251.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-23-055281.md) | [(0.1) d](/filings/0001193125-26-046984.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-182389.md) | [0.0 d](/filings/0001193125-26-318251.md) | not reported | not reported | [250](/filings/0001193125-26-182389.md) | [250 d](/filings/0001193125-26-318251.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [279](/filings/0000950170-23-055281.md) | [279](/filings/0000950170-24-047140.md) | [280](/filings/0000950170-24-085353.md) | [281](/filings/0000950170-24-117782.md) | [283](/filings/0000950170-25-059393.md) | [283](/filings/0000950170-25-099240.md) | [284](/filings/0001193125-25-251811.md) | [285](/filings/0001193125-26-182389.md) | [293](/filings/0001193125-26-318251.md) | [332](/filings/0001193125-25-251811.md) | [337](/filings/0001193125-26-182389.md) | [334](/filings/0001193125-26-318251.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 334,610,357 at 2026-07-24, from the cover of the [10-Q filed 2026-07-27](/filings/0001193125-26-318251.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.